JP2009518021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518021A5 JP2009518021A5 JP2008543852A JP2008543852A JP2009518021A5 JP 2009518021 A5 JP2009518021 A5 JP 2009518021A5 JP 2008543852 A JP2008543852 A JP 2008543852A JP 2008543852 A JP2008543852 A JP 2008543852A JP 2009518021 A5 JP2009518021 A5 JP 2009518021A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- cell
- tcr
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 39
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 108091008874 T cell receptors Proteins 0.000 claims 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 239000012636 effector Substances 0.000 claims 10
- 230000006870 function Effects 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 8
- 238000004520 electroporation Methods 0.000 claims 7
- 230000028327 secretion Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108010047620 Phytohemagglutinins Proteins 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 230000001717 pathogenic effect Effects 0.000 claims 4
- 230000001885 phytohemagglutinin Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000000284 resting effect Effects 0.000 claims 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 101710083889 Alpha-fetoprotein Proteins 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 101800001271 Surface protein Proteins 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000007885 magnetic separation Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000009711 regulatory function Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111928A EP1795599A1 (en) | 2005-12-09 | 2005-12-09 | Methods for generating antigen-specific effector T cells |
| US77958806P | 2006-03-06 | 2006-03-06 | |
| PCT/EP2006/069549 WO2007065957A2 (en) | 2005-12-09 | 2006-12-11 | Methods for generating antigen-specific effector t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518021A JP2009518021A (ja) | 2009-05-07 |
| JP2009518021A5 true JP2009518021A5 (enExample) | 2010-01-28 |
Family
ID=36691455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543852A Withdrawn JP2009518021A (ja) | 2005-12-09 | 2006-12-11 | 抗原特異的エフェクターｔ細胞の生成法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090226404A1 (enExample) |
| EP (2) | EP1795599A1 (enExample) |
| JP (1) | JP2009518021A (enExample) |
| KR (1) | KR20080077272A (enExample) |
| CN (1) | CN101415827A (enExample) |
| AU (1) | AU2006323961A1 (enExample) |
| CA (1) | CA2631785A1 (enExample) |
| WO (1) | WO2007065957A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
| WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
| JP2008521406A (ja) | 2004-11-24 | 2008-06-26 | フレッド ハッチンソン キャンサー リサーチ センター | 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法 |
| ES2341802T3 (es) * | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| DK2126054T3 (en) | 2007-01-31 | 2016-10-03 | Yeda Res & Dev | REROUTED, GENETICALLY MODIFIED regulatory T cells and their use for suppressing autoimmune inflammatory disease AND |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| WO2008097926A2 (en) * | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| GB0718160D0 (en) | 2007-09-18 | 2007-10-24 | Medical Res Council | Methods |
| WO2009045308A2 (en) * | 2007-10-03 | 2009-04-09 | Fred Hutchinson Cancer Research Center | Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression |
| KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| EP2090659A1 (en) * | 2008-02-14 | 2009-08-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Infectious particle, process for its preparation and use thereof |
| US8513208B2 (en) | 2008-02-28 | 2013-08-20 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| US20140161782A1 (en) * | 2008-06-09 | 2014-06-12 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
| JP6069755B2 (ja) | 2008-11-24 | 2017-02-01 | ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー | 高親和性ｔ細胞受容体およびその用途 |
| EP2393833A1 (en) * | 2009-02-09 | 2011-12-14 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP3213765B1 (en) * | 2010-09-20 | 2019-08-28 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| NZ743310A (en) * | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| CN110511278B (zh) | 2012-05-07 | 2024-08-09 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| CN108949694B (zh) * | 2012-09-11 | 2022-06-17 | 康宁有限公司 | 瞬时过表达编码药物转运蛋白和/或药物代谢酶的基因的可消耗的低温保存的细胞 |
| CN102911267B (zh) * | 2012-09-19 | 2014-04-02 | 南方医科大学 | 一种结核/hiv抗原肽双特异性tcr、其重组逆转录病毒载体与应用 |
| CA2934729C (en) * | 2014-01-29 | 2021-08-17 | University Health Network | Methods and compositions for producing a cell expressing a t cell receptor |
| WO2016095934A2 (en) * | 2014-12-14 | 2016-06-23 | El Abd Hisham Mohamed Magdy | A novel genetic device to engineer cell behavior |
| EP3256496B1 (en) | 2015-02-12 | 2020-12-30 | University Health Network | Chimeric antigen receptors |
| WO2017120428A2 (en) | 2016-01-06 | 2017-07-13 | Health Research, Inc. | Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors |
| JP6952225B2 (ja) * | 2016-03-18 | 2021-10-20 | 北海道公立大学法人 札幌医科大学 | Ｔ細胞レセプターとその利用 |
| CN109477073B (zh) * | 2016-03-31 | 2024-04-12 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
| HRP20250113T1 (hr) | 2016-06-02 | 2025-03-28 | Immunocore Limited | Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein |
| KR20200016224A (ko) * | 2017-05-02 | 2020-02-14 | 이뮤노믹 쎄라퓨틱스, 인크. | 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물 |
| CN107557339A (zh) * | 2017-09-19 | 2018-01-09 | 深圳市北科生物科技有限公司 | 特异性识别plac1的t细胞及其与细胞因子的联合的应用 |
| CN107630005A (zh) * | 2017-09-19 | 2018-01-26 | 深圳市北科生物科技有限公司 | 表达plac1特异性tcr的t细胞及其应用 |
| BR112020005361A2 (pt) | 2017-09-19 | 2020-09-24 | The University Of British Columbia | anticorpos anti-hla-a2 e métodos de uso dos mesmos |
| BR112020005519A2 (pt) | 2017-09-20 | 2020-10-27 | The University Of British Columbia | novos anticorpos anti-hla-a2 e usos dos mesmos |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
| WO2020010565A1 (zh) * | 2018-07-12 | 2020-01-16 | 深圳华大生命科学研究院 | Mart-1(27-35)表位特异性t细胞受体 |
| CA3150273A1 (en) * | 2019-08-08 | 2021-02-11 | Cedars-Sinai Medical Center | Method of generating activated t cells for cancer therapy |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| CN112941030B (zh) * | 2021-01-25 | 2023-08-08 | 吉林大学 | 一种抗原特异性Treg及其制备方法和应用 |
| EP4351595A1 (en) | 2021-06-07 | 2024-04-17 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| WO2024008274A1 (en) * | 2022-07-04 | 2024-01-11 | Universiteit Antwerpen | T regulatory cell modification |
| CN117797253A (zh) * | 2024-02-29 | 2024-04-02 | 诺未科技（北京）有限公司 | 一种能扩展t细胞抗原表位的肿瘤疫苗及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8211422B2 (en) * | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| EP1188825A1 (en) * | 2000-09-18 | 2002-03-20 | Universiteit Leiden | T cell receptor transfer into a candidate effector cell or a precursor thereof |
| US7723111B2 (en) * | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
| GB0111015D0 (en) * | 2001-05-04 | 2001-06-27 | Norsk Hydro As | Genetic material |
| CA2546378A1 (en) * | 2003-11-25 | 2005-06-09 | Argos Therapeutics, Inc. | Mrna transfected antigen presenting cells |
-
2005
- 2005-12-09 EP EP05111928A patent/EP1795599A1/en not_active Withdrawn
-
2006
- 2006-12-11 CN CNA2006800510949A patent/CN101415827A/zh active Pending
- 2006-12-11 WO PCT/EP2006/069549 patent/WO2007065957A2/en not_active Ceased
- 2006-12-11 JP JP2008543852A patent/JP2009518021A/ja not_active Withdrawn
- 2006-12-11 AU AU2006323961A patent/AU2006323961A1/en not_active Abandoned
- 2006-12-11 EP EP06830520A patent/EP1960527A2/en not_active Ceased
- 2006-12-11 US US12/086,106 patent/US20090226404A1/en not_active Abandoned
- 2006-12-11 CA CA002631785A patent/CA2631785A1/en not_active Abandoned
- 2006-12-11 KR KR1020087016698A patent/KR20080077272A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518021A5 (enExample) | ||
| Xie et al. | CAR-NK cells: A promising cellular immunotherapy for cancer | |
| Gao et al. | Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy | |
| Zhang et al. | Targeting natural killer cells for tumor immunotherapy | |
| Morandi et al. | Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on γδ T and NK cells | |
| US10351612B2 (en) | Interleukin 15 as selectable marker for gene transfer in lymphocytes | |
| Zimmermannova et al. | Cell fate reprogramming in the era of cancer immunotherapy | |
| Granzin et al. | Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma | |
| Cerwenka et al. | Natural killer cell memory in infection, inflammation and cancer | |
| Fang et al. | Challenges of NK cell-based immunotherapy in the new era | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| ES2816450T3 (es) | Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR | |
| ES2907581T3 (es) | Método mejorado para la generación de células genéticamente modificadas | |
| ES2963718T3 (es) | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras | |
| ES2959443T3 (es) | Uso del dominio de señalización de CD2 en receptores de antígenos quiméricos de segunda generación | |
| JP2017533706A5 (enExample) | ||
| Li et al. | Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy | |
| Wu et al. | Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy | |
| van der Veken et al. | αβ T cell receptor transfer to γδ T cells generates functional effector cells without mixed TCR dimers in vivo | |
| Anticoli et al. | Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells | |
| Faveeuw et al. | Optimization of natural killer T cell–mediated immunotherapy in cancer using cell-based and nanovector vaccines | |
| JP2017505621A5 (enExample) | ||
| Yuan et al. | Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy | |
| CN116507358A (zh) | 治疗癌症和自身免疫和炎性疾病的方法 | |
| US20240398950A1 (en) | Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells |